Rasagiline (cas 136236-51-6) monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan
-
Add time:08/29/2019 Source:sciencedirect.com
BackgroundRasagiline (cas 136236-51-6) is a monoamine oxidase type-B inhibitor in development in Japan for Parkinson's disease (PD). The objective of this Phase 3, randomized, double-blind study was to evaluate the efficacy and safety of rasagiline in Japanese patients with early PD (NCT02337725).
We also recommend Trading Suppliers and Manufacturers of Rasagiline (cas 136236-51-6). Pls Click Website Link as below: cas 136236-51-6 suppliers
Prev:Synthesis of the glucoallosamidin pseudo-disaccharide: Use of an efficient Hg(II) mediated cyclization
Next:Data articleSynthesis and characterization of 1-pyrindane derivatives as Rasagiline (cas 136236-51-6) analogues) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Regular articleEffect of long-term treatment with Rasagiline (cas 136236-51-6) on cognitive deficits and related molecular cascades in aged mice09/07/2019
- Research ReportRasagiline (cas 136236-51-6) prevents neurodegeneration in thiamine deficient rats—A longitudinal MRI study09/06/2019
- Rasagiline (cas 136236-51-6) in Parkinson's Disease09/05/2019
- Short communicationSimultaneous bioanalysis of Rasagiline (cas 136236-51-6) and its major metabolites in human plasma by LC–MS/MS: Application to a clinical pharmacokinetic study09/04/2019
- Protective effect of Rasagiline (cas 136236-51-6) in aminoglycoside ototoxicity09/03/2019
- Chemoenzymatic synthesis of Rasagiline (cas 136236-51-6) mesylate using lipases09/02/2019
- Original research articleEssential difference between the pharmacological spectrum of (−)-deprenyl and Rasagiline (cas 136236-51-6)09/01/2019
- Case ReportRasagiline (cas 136236-51-6) induced hypersexuality in Parkinson’s disease08/31/2019
- Data articleSynthesis and characterization of 1-pyrindane derivatives as Rasagiline (cas 136236-51-6) analogues08/30/2019